Urovant Entered into an Exclusive License Agreement with Pierre Fabre Médicament to Commercialize Vibegron for Overactive Bladder
Shots:
- Urovant to receive ~$75M in up front, regulatory & sales milestones along with royalties. Both companies will share responsibility for vibegron clinical trials in the pediatric populations in the EU
- Urovant also obtain full commercialization rights to vibegron in the US and other selected markets while Pierre Fabre will receive manufacturing services from Urovant. The companies collaborated to commercialize vibegron for OAB in the EEA, UK & Switzerland with option territories incl. french-speaking countries of SSA, Turkey & Eastern EU countries
- This collaboration affirms Pierre Fabre's expertise in urology & women's health for 5 decades and the group's aspirations to provide therapeutic treatments for chronic diseases
Ref: Bussinesswire | Image: Urovant Sciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
